Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 7Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Teratoma 1

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Triple Negative Breast Neoplasms × Gynecologic × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡